Dishman Carbogen Amcis Limited has submitted its quarterly compliance certificate to stock exchanges, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The pharmaceutical company filed the confirmation certificate for the quarter ended March 31, 2026, demonstrating its commitment to regulatory compliance.

Regulatory Compliance Submission

The company submitted the certificate on April 13, 2026, to both BSE Limited and National Stock Exchange of India Limited. The submission was made by Company Secretary Shrima Dave, who communicated with the respective listing departments of both exchanges.

Certificate Confirmation by RTA

MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, served as the Registrar and Share Transfer Agent (RTA) for this compliance process. The RTA issued the confirmation certificate on April 1, 2026, validating the company's adherence to dematerialisation requirements.

Key Confirmations Made

The RTA confirmed several critical aspects of securities handling during the quarter:

• Securities received from depository participants for dematerialisation were properly confirmed to depositories
• All securities comprised in certificates have been listed on stock exchanges where earlier issued securities are listed
• Security certificates received for dematerialisation were confirmed or rejected within prescribed timelines
• Received certificates were mutilated and cancelled after due verification by depository participants
• Depository names were substituted in the register of members as registered owners

Corporate Information

Dishman Carbogen Amcis Limited operates from its corporate house located on Iscon-Bopal Road, Ambli, Ahmedabad. The company maintains its registered operations in Ahmedabad, with pincode 380058.

The certificate was signed by Ashok Shetty, Sr. Vice President-Corporate Registry at MUFG Intime India Private Limited, ensuring proper authorization and validation of the compliance documentation. This quarterly submission reflects the company's ongoing commitment to maintaining transparency and regulatory adherence in its securities operations.

Dishman Carbogen Amcis Limited has obtained consent from its debenture trustee for waiving specific financial covenants on its Rs. 50 crore non-convertible debentures (NCDs) for the financial year ended March 31, 2026. The company received approval from Axis Trustee Services Limited on March 31, 2026, following its request dated February 23, 2026.

Debenture Details and Covenant Modifications

The waiver pertains to NCDs issued under ISIN INE385W07059, comprising 5,000 senior, secured, rated, listed, transferable, taxable, redeemable non-convertible debentures with a face value of Rs. 1,00,000 each. The debentures were issued on a private placement basis and are listed on BSE Limited.

Financial Performance Highlights

Despite seeking covenant waivers, the company demonstrated strong consolidated performance during 9MFY26. Revenue increased to Rs. 20,805 million compared to Rs. 19,952 million in 9MFY25, representing a 4.3% year-on-year growth.

The EBITDA margin improvement was driven by enhanced performance across both business segments. The CDMO segment margin expanded from 17.2% to 19.7% due to higher revenue contribution from late Phase III molecules, while the Marketable Molecules segment margin surged from 8.3% to 17.5% owing to increased Vitamin D analogues supplies and cost reduction measures.

Rationale for Covenant Waiver

The company attributed the need for covenant waivers to several external challenges affecting its standalone operations. Geopolitical issues, including tariffs and supply chain disruptions, led customers to adopt conservative procurement approaches and defer delivery schedules to FY2027. Additionally, some customers who previously lost market share due to past EDQM issues are working to regain their positions, causing delays in purchase orders for Indian facilities.

Business Outlook and Strategic Focus

Despite current challenges, the company maintains a positive outlook with a strong pipeline of 10 molecules in late Phase III development. The management is focusing on improving capacity utilization by targeting small and mid-sized global biotech companies and diversifying across new geographies. The company has been securing new contracts and issued a substantial number of RFQs, which are expected to generate incremental orders for FY27 and beyond.

The debenture trustee's consent ensures continued compliance with debt obligations while providing operational flexibility during challenging market conditions. The company emphasized that the waiver does not modify the tenure or redemption obligations of the debentures, maintaining its commitment to debt servicing.